Company Description
NeuroPace, Inc. operates as a medical device company in the United States.
The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support.
It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures.
NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Apr 22, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Joel Becker |
Contact Details
Address: 455 North Bernardo Avenue Mountain View, California 94043 United States | |
| Phone | (650) 237-2700 |
| Website | neuropace.com |
Stock Details
| Ticker Symbol | NPCE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001528287 |
| CUSIP Number | 641288105 |
| ISIN Number | US6412881053 |
| Employer ID | 22-3550230 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Joel D. Becker | Chief Executive Officer, President and Director |
| Rebecca L. Kuhn | Chief Financial Officer and Vice President of Finance and Administration |
| Dr. Martha J. Morrell M.D. | Chief Medical Officer |
| Dylan St. John | Chief of Operations and Development |
| Leah Akin | General Counsel and Corporate Secretary |
| Kelley Nicholas | Vice President of Sales |
| Katie Keller | Vice President of Marketing |
| Amy Treadwell | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 2, 2025 | 8-K | Current Report |
| Mar 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |